Skip to main content

Advertisement

SpringerLink
Log in

FDG uptake by the bone marrow in NSCLC patients is related to TGF-β but not to VEGF or G-CSF serum levels

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Introduction

Non small cell lung carcinomas (NSCLC) are known to secrete various cytokines such as VEGF (vascular endothelial growth factor), G-CSF (granulocyte-colony stimulating factor) and TGF-β (transforming growth factor-beta) that may stimulate bone marrow activity.

Purpose

This study reports on the relationship between serum levels of VEGF, G-CSF, TGF-β and FDG uptake by the bone marrow in NSCLC patients.

Methods

Thirty-three patients suffering from newly diagnosed NSCLC who were successively referred to undergo an FDG PET scan as a part of their routine staging procedure and that did not suffer from bone metastases were included in the study. FDG bone marrow activity was determined in all patients and related to pre-treatment VEGF, G-CSF and TGF-β serum levels.

Results

Mean standardized uptake values (SUV mean) of the bone marrow ranged from 0.1 to 2.1 (mean 1.1). G-CSF, VEGF and TGF-β serum levels ranged from 13.5 to 110 pg/ml (mean 41.4 pg/ml), from 95 to 3,221 pg/ml (mean 1,111 pg/ml) and from 269 to 615 pg/ml (mean 387 pg/ml), respectively. SUV mean values of the bone marrow significantly correlated with TGF-β serum measurements (r = 0.621, p < 0.0001), but not with VEGF and G-CSF measurements.

Conclusion

FDG uptake by bone marrow in newly diagnosed NSCLC patients correlates with serum levels of TGF-β, but not with VEGF or G-CSF levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Prévost S, Bocuher L, Larivée P, Boileau R, Bénard F. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 2006;47:559–65.

    PubMed  Google Scholar 

  2. Dudek A, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Investig 2005;23:193–200.

    Article  CAS  Google Scholar 

  3. Choi J, Kim H, Lim H, Nam D, Kim H, Yi J, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001;33:171–9.

    Article  PubMed  CAS  Google Scholar 

  4. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998;18:1251–4.

    PubMed  CAS  Google Scholar 

  5. Mroczko B, Szmitkowski M, Niklinski J. Granulocyte-colony stimulating factor and macrophage-colony stimulating factoring in patients with non-small cell lung cancer. Clin Chem Lab Med 2001;39:374–9.

    Article  PubMed  CAS  Google Scholar 

  6. Colasante A, Mascetra N, Brunetti M, Lattanzio G, Diodoro M, Caltagirone S, et al. Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small cell lung tumors. Am J Respir Crit Care Med 1997;156:968–73.

    PubMed  CAS  Google Scholar 

  7. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with non-small cell lung carcinoma. Cancer 2001;91:964–71.

    Article  PubMed  CAS  Google Scholar 

  8. Pacquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med 2004;5:784–8.

    Google Scholar 

  9. Souvatzoglou M, Ziegler S, Martinez M, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging; e-pub ahead of print: DOI 10.1007/s00259-006-0196-1.

  10. Tigue C, McKov J, Evans A, Trifilio S, Tallman M, Bennett C. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185–92; e-pub ahead of print.

    Google Scholar 

  11. Kazama T, Swanston N, Podoloff D, Macapinlac H. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406–11.

    Article  PubMed  CAS  Google Scholar 

  12. Kasuga I, Makino S, Kivokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leucocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92:2399–405.

    Article  PubMed  CAS  Google Scholar 

  13. Larrivee B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol 2005;175:3015–24.

    PubMed  CAS  Google Scholar 

  14. Gerber H, Malik A, Solar G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954–8.

    Article  PubMed  CAS  Google Scholar 

  15. D’Ambrosio D. Regulatory T cells: how do they find their space in the immunological arena. Semin Cancer Biol 2006;16:91–7.

    Article  PubMed  CAS  Google Scholar 

  16. Zou L, Barnett B, Safah H, LaRussa V, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD24+CD25+ regulatory T-cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004;64:5451–55.

    Google Scholar 

  17. Wahl S, Wen J, Moutsopoulos N. TGF-β: a mobile purveyor of immune privilege. Immunol Rev 2006;213–27.

  18. Liu V, Wong L, Jang T, Shah A, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD24+CD25- T cells into CD4+CD25+ regulatory cells: role of tumor derived TGF-b. J Immunol 2007;178:2883–92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Ghent, De Pintelaan 185B, 9000, Ghent, Belgium

    Christophe Van de Wiele & Frédéric VandeVyver

  2. Department of Clinical Chemistry, Microbiology and Immunology, University Hospital Ghent, Ghent, Belgium

    Caroline Debruyne & Jan Philippé

  3. Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium

    Jan P. van Meerbeeck

Authors
  1. Christophe Van de Wiele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frédéric VandeVyver
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline Debruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Philippé
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan P. van Meerbeeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christophe Van de Wiele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van de Wiele, C., VandeVyver, F., Debruyne, C. et al. FDG uptake by the bone marrow in NSCLC patients is related to TGF-β but not to VEGF or G-CSF serum levels. Eur J Nucl Med Mol Imaging 35, 519–522 (2008). https://doi.org/10.1007/s00259-007-0628-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0628-6

Keywords

Search

Navigation